MAPK1 and melanoma: While the observed decrease in active MEK levels in RocA-treated NRAS-mutant melanoma cells suggests that CRAF–PHB interactions may partly contribute to the control of ERK signaling, the concomitant loss of the negative feedback control leads to potent ERK hyperactivation also in this cellular context.